News

Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women A novel drug for the treatment of vulvovaginal atrophy based on prasterone (DHEA)   Geneva, the 02.06.2020 – On 19.05.2020, Swissmedic, the Swiss Agency for Therapeutic Products, granted a marketing authorization for the active substance prasterone for the local treatment of vulvovaginal […]

In line with our historic commitment to our healthcare partners, Labatec is continuing to multiply its efforts to help our customers and patients navigate the challenges of the COVID-19 pandemic. Now more than ever, we are taking action to ensure that our supply of essential medicines particularly used to treat COVID-19 patients remains uninterrupted despite […]

  Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland Production of Myring™ at the Mithra CDMO facility in Belgium Agreement follows licensing deals with major international market leaders forcommercialization of Myring™ Liege, Belgium, 05 December 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s […]